US2019314515A1PendingUtilityA1
Conjugates for treating diseases caused by psma expressing cells
Est. expiryNov 15, 2032(~6.3 yrs left)· nominal 20-yr term from priority
Inventors:Iontcho Radoslavov VlahovJoseph Anand ReddyAlicia BloomfieldRyan DortonMelissa NelsonMarilynn VetzelChristopher Paul Leamon
A61P 35/00A61P 13/08A61P 13/10A61K 47/64A61K 38/05A61K 38/06C07K 5/1019A61K 47/542A61K 38/07C07K 5/06113A61K 38/00C07K 5/021C07K 5/10A61K 38/08A61K 47/547A61K 51/04A61K 49/0002
69
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.
Claims
exact text as granted — not AI-modified1 . A conjugate of the formula
B-L-(D) n
or a pharmaceutically acceptable salt thereof, wherein B comprises a urea or thiourea of lysine and an amino acid, or one or more carboxylic acid derivatives thereof, including, but not limited to ureas or thioureas of lysine and aspartic acid, or glutamic acid, or homoglutamic acid, where the urea or thiourea is capable of binding to PSMA, L is a polyvalent linker, D is a radical of a drug, and n is an integer selected from 1, 2, 3, and 4.
2 - 29 . (canceled)Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.